Sequent Scientific Ltd (VIYASH) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Sequent Scientific reported strong Q4 FY25 results, with the highest quarterly revenue in recent years, continuing the trend of sequential growth.
- Q4 FY25 revenue reached INR 401.7 Crores, a 11.2% YoY increase.
- Pre-ESOP EBITDA grew by 38.7% YoY to INR 56.9 Crores, with a 14.2% margin, in line with guidance.
- FY25 revenue grew by 13% YoY to INR 1,551.6 Crores, and pre-ESOP EBITDA saw very healthy growth to INR 199 Crores.
- Strong momentum sustained throughout the year due to various initiatives undertaken to strengthen business fundamentals.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.